Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
about
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International StudyPrevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemiaEfficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level.Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitationLipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA RegistryAtorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.Risk prediction with triglycerides in patients with stable coronary disease on statin treatment.Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid.
P2860
Q30585937-5F4DD779-D6EF-4D68-B144-5BC7CF5F4290Q33630826-D918AA0D-4B02-4790-AD66-7540529002A1Q33669805-F92269E5-A992-44B4-8DA5-90BC7355696EQ33818871-6D3F4068-ACB4-4C83-8086-6E2185CE4ED2Q35576696-77BFEC46-A928-4DE6-80D8-FB8DAFD51D84Q35940422-33A71A61-4426-4EA2-92B1-F59E7CEA87AEQ36639121-B1A447CF-9E1E-4313-A463-8D782BA2C1DDQ37184508-7AA1388B-D342-4833-BE15-495D935FC399Q37653029-280F3A8C-6C41-473E-AE6B-BCABC774331EQ37972314-2D757D58-59A3-40A9-94EF-D98777104B94Q39424127-4618E34A-AA98-485B-B381-C1E71649C46BQ47255965-1339A9F3-1553-4C34-AC45-0CDC2900AD13Q51319217-4ECA2137-B9F3-46A6-8337-CD5289D60ED0Q55710149-686A84AD-2336-4C3D-86A5-500A7AFADB5B
P2860
Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevalence and overlap of diff ...... n clinical practice in Germany
@ast
Prevalence and overlap of diff ...... n clinical practice in Germany
@en
Prevalence and overlap of diff ...... n clinical practice in Germany
@nl
type
label
Prevalence and overlap of diff ...... n clinical practice in Germany
@ast
Prevalence and overlap of diff ...... n clinical practice in Germany
@en
Prevalence and overlap of diff ...... n clinical practice in Germany
@nl
prefLabel
Prevalence and overlap of diff ...... n clinical practice in Germany
@ast
Prevalence and overlap of diff ...... n clinical practice in Germany
@en
Prevalence and overlap of diff ...... n clinical practice in Germany
@nl
P2093
P2860
P1476
Prevalence and overlap of diff ...... n clinical practice in Germany
@en
P2093
Anselm K Gitt
Claus Jünger
Kurt Bestehorn
Wenefrieda Smolka
P2860
P2888
P304
P356
10.1007/S00392-010-0177-Z
P577
2010-06-03T00:00:00Z